Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China

Addiction

Volumn 110, Issue 5, 2015, Pages 796-802

  Zhou, Wang ^a   Wang, Xia ^a   Zhou, Sheng ^b   Xie, Nianhua ^a   Liu, Pulin ^a   Luo, Li ^a   Peng, Jinsong ^a   Liu, Manqing ^a   Desrosiers, Alethea ^c   Schottenfeld, Richard ^c   Chawarski, Marek C ^c  

^a Institute of Schistosomiasis Control   (China)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Behavioral risks; Hepatitis C virus; Injection drug use; Methadone maintenance treatment; Opiate dependence; Seroconversion

Indexed keywords

METHADONE;

ADULT; BLOOD; CHINA; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS C; HUMAN; MALE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; SEROCONVERSION; SUBSTANCE ABUSE;

ADULT; CHINA; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HUMANS; MALE; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SEROCONVERSION; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84927698775     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12836     Document Type: Article

References (31)

1. ® at http://www.webcitation.org/6QP7PVFIz).
2. Aceijas C., Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18: 362-358.
3. Shepard C. W., Finelli L., Alter M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
4. Xia X., Luo J., Bai J., Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health 2008; 122: 990-1003.
5. Garten R. J., Lai S., Zhang J., Liu W., Chen J., Vlahov D., et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol 2004; 33: 182-8.
6. Christensen P. B., Krarup H. B., Niesters H. G., Norder H., Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol 2000; 16: 1043-9.
7. Maher L., Li J., Jalaludin B., Chant K. G., Kaldor J. M. High hepatitis C incidence in new injecting drug users: a policy failure? Aust NZ J Public Health 2007; 31: 30-5.
8. Roy E., Alary M., Morissette C., Leclerc P., Boudreau J. F., Parent R., et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J STD AIDS 2007; 18: 23-7.
9. Hahn J. A., Page-Shafer K., Lum P. J., Bourgois P., Stein E. Evans J. L., et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002; 186: 1558-64.
10. Narcotics Control Bureau of the Chinese Ministry of Public Security. Annual Report on Drug Control in China: 2013.
11. Bao Y. P., Liu Z. M. Systematic review of HIV and HCV infection among drug users in China. Int J STD AIDS 2009; 20: 399-405.
12. ® at http://www.webcitation.org/6QP7qbU7r).
13. Pang L., Hao Y., Mi G., Wang C., Luo W., Rou K., et al. Effectiveness of first eight methadone maintenance treatment clinics in China. AIDS 2007; 21(Suppl 8): S103-7.
14. Wu Z., Sullivan S. G., Wang Y., Rotheram-Borus M. J., Detels R. Evolution of China's response to HIV/AIDS. Lancet 2007; 369: 679-90.
15. Sullivan S. G., Wu Z. Rapid scale up of harm reduction in China. Int J Drug Policy 2007; 18: 118-28.
16. ® at http://www.webcitation.org/6QP821iaO).
17. Yin W., Hao Y., Sun X., Gong X., Li F., Li J., et al. Scaling up the national methadone maintenance treatment program in China: achievements and challenges. Int J Epidemiol 2010; 39(Suppl 2): 29-37.
18. National Center of AIDS Prevention and Control (NCAIDS) Annual Report 2013. Unpublished document.
19. Metzger D. S., Woody G. E., McLellan A. T., O'Brien C. P., Druley P., Navaline H., et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993; 6: 1049-56.
20. Willner-Reid J., Belendiuk K. A., Epstein D. H., Schmittner J., Preston K. L. Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. J Subst Abuse Treat 2008; 35: 78-86.
21. Liu E. W., Liang T., Shen L. M., Zhong H., Wang B., Wu Z. Y., et al. [Impact of methadone maintenance treatment on HIV risk behaviors of heroin drug users]. Zhonghua Yu Fang Yi Xue Za Zhi 2010; 44: 981-4.
22. Crofts N., Nigro L., Oman K., Stevenson E., Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 1997; 92: 999-1005.
23. Selvey L. A., Denton M., Plant A. J. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: factors influencing hepatitis C serostatus. Aust NZ J Public Health 1997; 21: 102-4.
24. Thiede H., Hagan H., Murrill C. S. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health 2000; 77: 331-45.
25. Breslow N., Day N. Statistical Methods in Cancer Research. Vol. 2. The Design and Analysis of Cohort Studies. Lyon, France: International Agency for Research on Cancer: IARC Scientific Publications; 1987.
26. Lin C., Wu Z., Rou K., Yin W., Wang C., Shoptaw S., et al. Structural-level factors affecting implementation of the methadone maintenance therapy program in China. J Subst Abuse Treat 2010; 38: 119-27.
27. Raffa J. D., Grebely J., Tossonian H., Wong T., Viljoen M., Khara M., et al. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program. Drug Alcohol Depend 2007; 89: 306-9.
28. Vickerman P., Martin N., Turner K., Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in HCV prevalence? Model projections for different epidemic settings. Addiction 2012; 107: 1984-95.
29. Van Den Berg C., Smit C., Van Brussel G., Coutinho R., Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 1454-562.
30. Martin N. K., Hickman M., Hutchinson S. J., Goldberg D. J., Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57(Suppl 2): 39-45.
31. Hagan H., Pouget E. R., Des Jarlais, D. C. A systematic review and meta-anlysis of interventions to prevent hepatitis C virus infections in people who inject drugs. J Infect Dis 2011; 204: 74-83.